Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compounds for use in the treatment of feline retroviral infections

A technology of compounds and solvates, which can be used in the fields of compounds, antiviral agents, and drug combinations of elements of Group 5/15 of the periodic table, which can solve problems such as inability to avoid infection and inability to induce sterile immunity.

Inactive Publication Date: 2014-07-09
阿拉塔纳医疗有限公司
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These experiments confirm that FeLV vaccination neither induces sterile immunity nor protects against infection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compounds for use in the treatment of feline retroviral infections
  • Compounds for use in the treatment of feline retroviral infections
  • Compounds for use in the treatment of feline retroviral infections

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0133] Example 1: Inhibition of Feline Leukemia Virus Replication by R-PMPDAP in Cell Culture

[0134] Materials and Methods

[0135] The compound was dissolved in 0.05N sodium hydroxide solution at a concentration of 10 mg / ml. Crandell Reese feline kidney (CrFK) cells were grown in Dulbecco's minimal essential medium (DMEM, Life Technologies) supplemented with 1% sodium bicarbonate (Life Technologies) and 5% fetal calf serum (FCS, Biochrom). In a 96-well plate, seed 5000 CRFK cells and store at 37°C with 5% CO 2 Incubate for 24 h in a humid atmosphere. Cells were subsequently washed with 100 μl of phosphate-buffered saline (PBS) containing 50 μg / ml DEAE-dextran and seeded at 100 CCID in the presence of increasing doses of compound (0.4, 2, 10 and 50 μg / ml) 50 FeLV. After incubation for 2 h to allow the virus to enter the cells, the supernatant was removed and the cells were washed with PBS. DMEM containing 5% FCS with increasing doses of compound was added to infected ...

Embodiment 2

[0140] Embodiment 2: R-PMPDAP treatment to the clinical disease cat of natural infection FIV

[0141] Materials and Methods

[0142] Compounds are dissolved in a suitable aqueous buffered sodium hydroxide solution at near neutral pH conditions (pH 6-9) to a concentration of 50-250 mg / mL.

[0143] The formulated compound is administered by the subcutaneous route at least once a week at a total dosage rate of 10-175 mg / kg per week. The duration of treatment is from 1 week to 3 months. Treated cats were clinically diseased cats naturally infected with FIV and exhibited various symptoms.

[0144] result

[0145] Treatment outcomes for cats with specific symptoms are discussed below.

[0146] • Cats with oral signs.

[0147] Oral signs may manifest themselves, but are not limited to, stomatitis, gingivitis, laryngitis, glossitis, periodontitis, gingivostomatitis, tonsil and tongue ulcers, salivation, and the like. Examples of the effect of said compounds in the treatment ...

Embodiment 3

[0170] Example 3: R-PMPDAP Treatment of Cats Naturally Infected with FeLV

[0171] Materials and Methods

[0172] The compound is dissolved in an appropriate aqueous buffered sodium hydroxide solution at a concentration of 50-250 mg / ml and near neutral pH conditions (pH 6-9). The formulated compound is administered by the subcutaneous route at least once a week at a total dosage rate of 10-175 mg / kg per week. The duration of treatment is from 1 week to 3 months.

[0173] result

[0174] ●Cats with high viral loads (viremic cats)

[0175] FeLV-positive female cats whose FeLV viral load was quantified using RT-qPCR (Cattori and Hofmann-Lehmann, 2008) were treated with the compounds. Viral load decreased significantly from 15500 FeLV virions / mL plasma to 3200 FeLV virions / mL plasma.

[0176] ●Clinically symptomatic cats

[0177] FeLV-positive male cats with FeLV-related clinical signs such as stomatitis, lymphadenopathy, diarrhea, etc. resulting in a low Karnofsky score...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

The present invention relates tocompounds and compositions for use in the treatment or prevention of retroviral infections in felines, in particular cats, and to the use of said derivatives for the manufacture of a medicament for the treatment or prevention of feline leukemia virus (FeLV) infections occurring alone or together with feline immunodeficiency virus (FIV) infections in cats.

Description

technical field [0001] The present invention relates to compounds and compositions for the treatment or prevention of retroviral infections in felines, especially cats, and to the preparation of said derivatives for the treatment or prevention of feline leukemia virus ( FeLV) infection or the purposes in the medicine of the feline leukemia virus (FeLV) infection that occurs together with feline immunodeficiency virus (FIV) infection. Background technique [0002] Feline immunodeficiency virus (FIV) and feline leukemia (FeLV) infections are widespread: more than 8 percent of all domestic cats (Felis catus) are infected with FIV, and up to 14 percent are infected with FeLV (Table 1). Cats are one of the most popular and widespread pet animals. There are more than 400 million domestic cats in the world, mainly in Europe and the United States. [0003] Table 1: Prevalence of FIV (Courchamp, 1996) and FeLV [0004] Infect FIV FeLV North America 8.1% n.a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/662A61P31/14
CPCA61K31/662A61P31/14A61P43/00C07F9/65583
Inventor 尼娜·尤斯塔凯特琳·哈特曼西尔维·达米内特马里耶拉·戴比勒乔瑞·奥威尔斯尼斯亚·戈里斯斯特凡·维拉埃尔文·布洛斯玛阿伊努·比利叶简·思文伯特·乌兰克斯维利·德贝米约翰·奈茨
Owner 阿拉塔纳医疗有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com